Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mivacurium is a short-acting, non-depolarizing neuromuscular blocking agent used to induce skeletal muscle relaxation during surgical procedures or while on mechanical ventilation. It acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor endplate, inhibiting the action of acetylcholine and thereby blocking neuromuscular transmission. Mivacurium is hydrolyzed by plasma cholinesterase, resulting in rapid recovery after discontinuation. Its primary indications are for facilitating tracheal intubation and providing muscle relaxation during surgery or mechanical ventilation[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mivacurium.